Improving Dementia Caregiver Sleep & the Effect on Heart Disease Biomarkers
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Caregivers of Persons With Dementia
- Sponsor
- University of South Florida
- Enrollment
- 80
- Locations
- 1
- Primary Endpoint
- Sleep Efficiency (SE)
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
The purpose of the study is to determine whether a combined intervention of a night home monitoring system and cognitive-behavioral therapy for insomnia (CBTi) is effective in improving sleep in dementia caregivers who arise at night.
Detailed Description
Informal caregivers provide the majority of care for chronically ill adults, including persons with dementia. While these individuals provide a great benefit to the chronically ill relative, being a caregiver is associated with deleterious health consequences, including premature mortality and higher rates of coronary heart disease (CHD). Another common complaint among dementia caregivers is poor sleep, which has been connected to premature mortality and higher rates of CHD in noncaregiving adults. Currently no sleep therapies are empirically validated as effective for caregivers of persons with dementia (PWD), and since PWD often arise at night, improving caregiver sleep could be potentially hazardous as a sleeping caregiver cannot provide supervision during night awakenings. Our primary purpose is thus to determine whether a combined intervention is effective in improving sleep in caregivers of PWD who arise at night. The intervention consists of a night home monitoring system that provides reliable alerts to caregivers when PWD leave the bed and move through the house. While this system improved home safety for PWD, it did not affect caregiver sleep, so a more traditional sleep therapy will be added-cognitive-behavioral therapy for insomnia. In the proposed study, experimental participants will receive the night home monitoring system + CBTi; active comparator participants will receive the night home monitoring system and sleep behavioral therapy. Participants will remain in the study for 29 weeks, with 4 data collection points. We hypothesize experimental participants will have less time awake after going to bed, and improved sleep efficiency (percent time asleep while in bed). Sleep data will be collected for multiple nights using actigraphy and sleep diary. Our secondary research questions focus on the relationship between poor sleep and CHD. Both in adults and in dementia caregivers, there appears to be a link between poor sleep and abnormal levels on coronary heart disease biomarkers, and likely an increase in CHD with poor sleep. We aim to further explore this relationship as well as determine whether levels of biomarkers improve with improved sleep from the intervention. We propose to draw blood samples at 4 data collection points and measure a set of biomarkers indicative of CHD.
Investigators
Meredith Rowe
Meredeth A. Rowe, RN, PhD Professor and Lewis & Leona Hughes Endowed Chair
University of South Florida
Eligibility Criteria
Inclusion Criteria
- •Primary caregiver for a relative who has been diagnosed by a physician with dementia or Alzheimer's disease.
- •Persons with dementia sleep in the same location each night.
- •Caregiver provides care for persons with dementia with nighttime activity that occurs at least one night/week.
- •Caregiver meets the standard criteria for Insomnia.
- •Caregiver sleep problems affect daytime functioning.
- •If caregiver uses sleep medication, dose stable for 6 months.
- •Caregiver Telephone Interview for Cognitive Status Score \>
- •Caregiver does not require assistive devices to walk in the home at night.
Exclusion Criteria
- •Caregiver receives respite care at night the majority of the time.
- •Caregiver has diagnosed sleep disorder.
- •Caregiver uses CPAP at night
- •Caregiver has chronic illness that requires frequent, weekly treatment/assessment by a healthcare provider.
- •Current use of anticoagulant medication by the caregiver.
- •Caregiver Sleep Apnea-Hypopnea Index (AHI) score \> 10 or \> 15 if pulse oximetry ≥ 88%.
- •Caregiver shows evidence of Restless Leg Syndrome per the Cambridge-Hopkins Restless Leg Syndrome Questionnaire.
- •Montreal Cognitive Assessment (MOCA) score \< 26.
Outcomes
Primary Outcomes
Sleep Efficiency (SE)
Time Frame: Week 27-28
Actigraphy, using the Actiwatch2, will be used to measure objective sleep; We will collect data for 14-day periods using a 30-second epoch length to accurately capture night-to-night variability. Subjects will also complete a sleep diary for each day of actigraphic data collection, which will provide subjective sleep values of SE. Data collected include bedtime, sleep start, number awakenings, minutes awake during night, wake time, out-of-bed time, minutes spent napping the previous day, and a sleep quality rating.
Total Wake Time (TWT)
Time Frame: Week 27-28
Actigraphy, using the Actiwatch2, will be used to measure objective sleep; We will collect data for 14-day periods using a 30-second epoch length to accurately capture night-to-night variability. Subjects will also complete a sleep diary for each day of actigraphic data collection, which will provide subjective sleep values of TWT. Data collected include bedtime, sleep start, number awakenings, minutes awake during night, wake time, out-of-bed time, minutes spent napping the previous day, and a sleep quality rating.
Nighttime Injuries
Time Frame: Week 27-28
The Caregiver will be asked about any PWD injuries that occurred since the last data collection point. Injuries will be coded according to the American National Standards method of recording injuries. The following data are collected: nature of injury; part of the body affected; object, substance, exposure, or bodily motion that caused the injury; event that directly resulted in the injury; and time and place of the injury's occurrence. An injury will be considered nighttime if the caregiver reported being asleep at the time the injury occurred.
Secondary Outcomes
- D-Dimer Levels(Week 27)
- C-reactive Protein (CRP) Levels(Week 27)
- Intercellular Adhesion Molecule-1 (ICAM-1)(Week 27)
- IL-6, and TNFα Levels(Week 27)
- Tissue Plasminogen Activator Levels(Week 27)